Chargement en cours...
Overcoming resistance to cetuximab with honokiol, a small-molecule polyphenol
Overexpression and activation of the Epidermal Growth Factor Receptor (EGFR) have been linked to poor prognosis in several human cancers. Cetuximab is a monoclonal antibody against EGFR, that is used for the treatment in head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer....
Enregistré dans:
| Publié dans: | Mol Cancer Ther |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5752575/ https://ncbi.nlm.nih.gov/pubmed/29054984 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0384 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|